TCB Team is a group of domain experts and writers focused on biotech, healthcare, and AI. They deliver original, high-signal coverage tailored for industry professionals, investors, and researchers. With a neutral and independent voice, the team transforms complex developments into clear, actionable insights.
110 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryPfizer’s strategic move to fast-track its obesity treatment follows critical patent cliffs on key products. The accelerated development timeline reflects the company’s proactive efforts to sustain its market presence and address a growing public health concern.
TCB TeamJan 13, 2026
Regulatory & PolicyAt a recent STAT event, Richard Pazdur, who departed the FDA after 26 years of service, delivered a stark warning regarding the current state of the FDA. He discussed how political influences and internal disarray are damaging the agency’s core functions and ability to safeguard public health. Pazdur's observations come at a critical time as regulatory policies and agency leadership face unprecedented scrutiny.
TCB TeamJan 13, 2026
Regulatory & PolicyThe push by major drugmakers to update FDA post-approval change rules highlights ongoing regulatory challenges that affect the pharmaceutical supply chain and manufacturing sovereignty. The companies' advocacy underscores the importance of regulatory adaptability to keep pace with industry needs and global supply dynamics, particularly as reshoring production gains prominence in policy discussions.
TCB TeamJan 13, 2026
Biopharmaceutical IndustryAbbVie's significant investment signals a strategic effort to strengthen its oncology pipeline through a novel bispecific antibody developed in China. Targeting PD-1 and VEGF, the modality is at the forefront of emerging cancer therapies vying for market dominance.
TCB TeamJan 13, 2026
Biopharmaceutical IndustryWhile many large biopharma companies prioritize late-stage asset acquisitions, Bristol Myers Squibb is the notable exception actively securing partnerships with early-stage biotech innovators. Its collaborations with companies like insitro and Orbital Technologies illustrate a forward-looking approach aiming to shape the future of biopharmaceutical innovation.
TCB TeamJan 13, 2026
AI in Drug DiscoveryAt JPM 2026, Nvidia unveiled significant partnerships with leading pharma and life sciences companies including Eli Lilly and Thermo Fisher, illustrating its ambition to become a critical technology provider underpinning AI innovation in drug discovery and research laboratories worldwide.
TCB TeamJan 13, 2026
AI in Drug DiscoveryBoth Anthropic and OpenAI are expanding their large language models into the healthcare sector, employing different strategies to integrate AI tools that address a variety of healthcare needs. Understanding their platforms’ design and targeted users offers insights into the evolving role of AI in medicine.
TCB TeamJan 12, 2026
Biopharmaceutical IndustryFacing challenges with the commercial performance of its flagship product, Alnylam is charting a course for growth and resilience. This plan reflects a commitment to advancing gene-silencing technology and expanding their pipeline to meet unmet medical needs.
TCB TeamJan 12, 2026
Regulatory & PolicyThe dialogue between Stoke Therapeutics and the FDA surrounding the expedited review of a promising severe epilepsy drug underscores the complexities facing regulatory approvals in neurology. This development highlights ongoing tensions in balancing regulatory rigor with the urgent needs of patients with rare and debilitating conditions.
TCB TeamJan 11, 2026
Medical TechnologyThe infusion of $4.6 million in capital reflects growing investor confidence in artificial intelligence's potential to transform behavioral health care. Oasys Health aims to leverage this funding to develop technology solutions that better support mental health conditions through machine learning and personalized intervention.
TCB TeamJan 11, 2026
AI in Drug DiscoveryThe healthcare AI landscape has witnessed rapid innovation, with personalized health information tools becoming increasingly vital. Microsoft's initial foray with an AI product integrating deeply in health records has not seen recent developments, raising questions about strategic execution in this competitive domain.
TCB TeamJan 11, 2026
Regulatory & PolicyThe National Institutes of Health (NIH), a cornerstone of biomedical research and public health advancement, is currently facing a critical juncture as four leading officials have publicly resigned. Their departure raises important questions about scientific independence and institutional integrity amid alleged interference and censorship within the agency.
TCB TeamJan 11, 2026